Version 1
: Received: 30 November 2022 / Approved: 1 December 2022 / Online: 1 December 2022 (10:33:14 CET)
How to cite:
Omar, N. E. The Financial Toxicity of Advanced Hepatocellular Carcinoma Treatment in Low Middle-Income Countries. Preprints2022, 2022120026. https://doi.org/10.20944/preprints202212.0026.v1
Omar, N. E. The Financial Toxicity of Advanced Hepatocellular Carcinoma Treatment in Low Middle-Income Countries. Preprints 2022, 2022120026. https://doi.org/10.20944/preprints202212.0026.v1
Omar, N. E. The Financial Toxicity of Advanced Hepatocellular Carcinoma Treatment in Low Middle-Income Countries. Preprints2022, 2022120026. https://doi.org/10.20944/preprints202212.0026.v1
APA Style
Omar, N. E. (2022). The Financial Toxicity of Advanced Hepatocellular Carcinoma Treatment in Low Middle-Income Countries. Preprints. https://doi.org/10.20944/preprints202212.0026.v1
Chicago/Turabian Style
Omar, N. E. 2022 "The Financial Toxicity of Advanced Hepatocellular Carcinoma Treatment in Low Middle-Income Countries" Preprints. https://doi.org/10.20944/preprints202212.0026.v1
Abstract
Advanced Hepatocellular carcinoma (HCC) is no longer a terminal illness. This change was mainly attributed to the development of new treatments including tyrosine-kinase inhibitors (TKIs), vascular endothelial growth factor (VEGF) inhibitors and immune checkpoint inhibitors (ICPIs) but the financial toxicity of treating advanced HCC is of a major concern specially in low middle-income countries (LMICs) where the patients are still battling for their most basic rights. Most of advanced HCC patients in LMICs have very limited accessibility to the new treatments including ICPIs. Searching for out of the box solutions to improve access to treatments -mainly ICPIs- is an utmost necessity for LMICs advanced HCC patients.
Medicine and Pharmacology, Oncology and Oncogenics
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.